Peanut Patch Results Released As Allergy Meeting Begins – AJMC.com Managed Markets Network
Despite the finding that a phase 3 trial of an epicutaneous immunotherapy therapy for peanut allergy did not achieve the lower end of an efficacy endpoint, it may still represent a viable option for children with peanut allergy, considering the unpredictability of these severe and sometimes fatal reactions. Despite the finding that a phase 3… Read More »